Metabolic dysfunction-associated steatotic liver disease and gastroesophageal reflux disease: a mendelian randomization study in European and East Asian populations

被引:0
|
作者
Su, Chen'guang [1 ]
Liao, Zheng [1 ]
Li, Hewen [2 ]
Pei, Yinxuan [1 ]
Wang, Zixiang [1 ]
Li, Jian [1 ]
Liu, Jinlong [1 ,3 ]
机构
[1] Chengde Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp, Chengde, Hebei, Peoples R China
[2] Chengde Med Univ, Dept Minimally Invas Spine Surg, Affiliated Hosp, Chengde, Hebei, Peoples R China
[3] Hebei Key Lab Panvasc Dis, Chengde, Hebei, Peoples R China
关键词
metabolic dysfunction-associated steatotic liver disease; gastroesophageal reflux disease; mendelian randomization; causal effect; genome-wide association studies; ALANINE AMINOTRANSFERASE; RISK-FACTORS; ESOPHAGITIS; PREVALENCE; OBESITY; INSTRUMENTS; SYMPTOMS; BIAS;
D O I
10.3389/fgene.2024.1428334
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Numerous observational studies have shown a potential association between metabolic dysfunction-associated steatotic liver disease (MASLD) and gastroesophageal reflux disease (GERD). However, causality is unclear. This study utilized genome-wide association study (GWAS) genetic data to explore the causal relationship between MASLD and GERD in European and East Asian populations. Methods This study utilized a bidirectional, two-sample Mendelian randomization (MR) approach. All disease data were obtained from the GWAS database, and single nucleotide polymorphisms strongly associated with exposure were selected as instrumental variables. The inverse variance weighted (IVW) method is primarily utilized to evaluate the causal relationship between exposure and outcome. Finally, sensitivity analyses were performed to ensure the robustness of the results. Results The IVW estimates indicated that non-alcoholic fatty liver disease (NAFLD) (odds ratio (OR) = 1.054, 95% confidence interval (CI), 0.966-1.150, p = 0.236) and percent liver fat (OR = 0.977, 95% CI, 0.937-1.018, p = 0.258) in European population were not linked to a higher risk of GERD. However, GERD in European population was associated with an increased risk of NAFLD (OR = 1.485, 95% CI, 1.274-1.729, p < 0.001) and percent liver fat (OR = 1.244, 95% CI, 1.171-1.321, p < 0.001). In addition, the IVW analysis in East Asian population showed that alanine aminotransferase (ALT) was associated with an increased risk of GERD (OR = 2.305, 95% CI, 1.241-4.281, p = 0.008), whereas aspartate aminotransferase (AST) had no causal effects on GERD risk (OR = 0.973, 95% CI, 0.541-1.749, p = 0.926). Furthermore, the associations between GERD and ALT (OR = 1.007, 95% CI, 0.998-1.015, p = 0.123) or AST (OR = 1.004, 95% CI, 0.997-1.012, p = 0.246) were not significant. After removing outliers, a significant correlation between GERD and ALT was observed (OR = 1.009, 95% CI, 1.001-1.016, p = 0.020). Conclusion There was reverse causality between MASLD and GERD in European population, while there was bidirectional causality between a proxie for MASLD (ALT) and GERD in East Asian population. This study can provide novel insights into cross-ethnic genetic research on MASLD and GERD.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [42] Progress in the Study of Animal Models of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Fu, Yu
    Hua, Yuxin
    Alam, Naqash
    Liu, Enqi
    NUTRIENTS, 2024, 16 (18)
  • [43] Metabolic dysfunction-associated steatotic liver disease and cancer risk: A cohort study
    Peng, Yu
    Wang, Peng
    Liu, Fubin
    Wang, Xixuan
    Si, Changyu
    Gong, Jianxiao
    Zhou, Huijun
    Gu, Jiale
    Qin, Ailing
    Song, Weijie
    Song, Fangfang
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 1940 - 1949
  • [44] Association between metabolic dysfunction-associated steatotic liver disease and pulmonary function: a population-based and two-sample mendelian randomization study
    Feng, Ting
    Li, Jiaming
    Wu, Lihao
    He, Xingxiang
    Ye, Junzhao
    BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [45] Metabolic Dysfunction-Associated Steatotic Liver Disease vs. Metabolic Dysfunction-Associated Fatty Liver Disease: Which Option is the Better Choice?
    Gambardella, Maria Luisa
    Abenavoli, Ludovico
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2025, 86 (02)
  • [46] Serum folate levels and risk of metabolic dysfunction-associated steatotic liver disease: results from a cross-sectional study and Mendelian randomization analysis
    Chen, Yalan
    Gao, Jie
    Wang, Xibin
    Lu, Hong
    Zheng, Ya
    Ren, Qian
    FRONTIERS IN NUTRITION, 2024, 11
  • [47] Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease
    Long, Qichen
    Luo, Fengming
    Li, Binghui
    Li, Ziyang
    Guo, Zhe
    Chen, Zhiyang
    Wu, Weimin
    Hu, Min
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (03)
  • [48] The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
    Sawada, Keisuke
    Chung, Hak
    Softic, Samir
    Moreno-Fernandez, Maria E.
    Divanovic, Senad
    CELL METABOLISM, 2023, 35 (11) : 1852 - 1871
  • [49] Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease
    Gulati, Reeti
    Moylan, Cynthia A.
    Wilder, Julius
    Wegermann, Kara
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (02):
  • [50] METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IS ASSOCIATED WITH LIVER FIBROSIS IN HEPATITIS C
    Elgretli, Wesal
    Shengir, Mohamed
    Sasson, Solomon
    Agnihotram, V. Ramanakumar
    Ballesteros, Luz Esther Ramos
    Deschenes, Marc
    Wong, Philip
    Chen, Tianyan
    Kronfli, Nadine
    Keeshan, Alexa
    Tandon, Saniya
    Cooper, Curtis
    Sebastiani, Giada
    HEPATOLOGY, 2024, 80 : S382 - S383